Infliximab Biosimilar Market Future Trends and Scope Analysis Report 2023-2030

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

Get Free Sample Copy of Report :https://www.insightaceanalytic.com/request-sample/1060

According to the latest research by InsightAce Analytic, the global Infliximab Biosimilar market is valued at US$ XX Million in 2021, and it is expected to reach US$ XX Million by 2030, with a CAGR of XX% during a forecast period of 2022-2030.

Infliximab is a tumour necrosis factor alpha (TNF-) chimeric monoclonal antibody. Ankylosing spondylitis, Crohn's disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis are all conditions treated with it. The biosimilar Infliximab is just as effective and safe as the original biologic medication. Remicade is the brand name for it. A recombinant cell line grown by continuous perfusion produces infliximab. Tumor necrosis factor-alpha (TNF-) is a proinflammatory cytokine that plays an important role in chronic inflammatory disorders.

The rising prevalence of autoimmune diseases, particularly plaque psoriasis and rheumatoid arthritis, the early patent expiration of the branded version, reduced pricing across the European market, and quicker response times due to intravenous mode of administration are all driving factors for the Infliximab biosimilar. Governmental and third-party payer measures to cut costs have promoted the use of infliximab biosimilars, which has increased demand for infliximab biosimilars. Other elements boosting demand for infliximab biosimilars are cost effectiveness, rising chronic disease rates (including cancer and autoimmune diseases), and an ageing population. The market expansion for biosimilars is being hampered by a few factors. This includes poor physician opinion, a smaller price premium over small-molecule generics, extended patent protection, etc. The worldwide infliximab market is also constrained by adverse medication reactions such histoplasmosis (a fungal infection), bacterial sepsis, tuberculosis (TB), and others.

Europe dominated the biosimilars market, followed by Asia-Pacific and North America. Several factors are driving growth in these markets, including the upcoming patent expiration of biological drugs and the introduction of new biosimilars, the rise of new businesses and early market entry. North America is anticipated to be the major contributor to the Infliximab Biosimilar market over the forecast years. The global market is driven by the rise in the prevalence of autoimmune and genetic conditions such as plaque psoriasis and rheumatoid arthritis. The market is developing as a result of rising geriatric populations that lack access to suitable diagnostic and therapeutic options, improved health care infrastructure, and untapped markets. The worldwide infliximab biosimilars market in this region is also predicted to be driven by an increase in government funding for the production of biosimilar medicines as well as increased awareness and adoption of biosimilars.

Major market players operating in the Infliximab Biosimilar market include
Napp Pharmaceuticals Group Ltd, Alvogen, Merck &Co. Inc., Celltrion Inc., Janssen Biotech Inc., Pfizer Inc. (AC. Hospira), and Nippon Kayaku.

Recent collaborations and agreements in the market:
In April 2021, Novartis AG (Sandoz) struck a deal with Bio-Thera Solutions (China) to commercialise BAT1706 (Bio-Thera Solutions' proposed bevacizumab biosimilar) in the United States, Canada, Europe, and other international markets.
In November 2019, Biogen Inc, a multinational biotechnology company headquartered in Cambridge, Massachusetts, purchased Samsung Bioepis Co., Ltd. in order to obtain exclusive rights to market two new ophthalmology biosimilars, SB11 referencing Lucentis 1 and SB15 referencing Eylea 2, in major markets around the world, including the United States, Canada, Europe, Japan, and Australia. The deal allows Biogen to prolong the commercialization time for Samsung Bioepis' three anti-TNF biosimilars, BENEPALI (etanercept), FLIXABI (infliximab), and IMRALDI, in Europe (adalimumab). Samsung Bioepis is a biopharmaceutical company. It makes biosimilar medications and other related products.

Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1060

Market Segments
Global Infliximab Biosimilar Market, by Application, 2022-2030 (Value US$ Mn)
Crohn's Disease
Psoriatic Arthritis
Rheumatoid Arthritis
Ulcerative Colitis
Ankylosing Spondylitis
Plaque Psoriasis and others

Global Infliximab Biosimilar Market, by End User, 2022-2030 (Value US$ Mn)
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Other Direct Distribution Channels

Global Infliximab Biosimilar Market, by Mode, 2022-2030 (Value US$ Mn)
Prescription-Based Testing Products
Over-the-Counter (OTC) Testing Product

Global Infliximab Biosimilar Market, by End-Users, 2022-2030 (Value US$ Mn)
Home Care/Self Testing
Physician offices & Outpatient/Ambulatory Care Settings
Hospitals
Research Laboratories

Global Infliximab Biosimilar Market, by Region, 2022-2030 (Value US$ Mn)
North America
Europe
Asia Pacific
Latin America
Middle East & Africa

North America Infliximab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
U.S.
Canada

Europe Infliximab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
Germany
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific Infliximab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
India
China
Japan
South Korea
Australia & New Zealand

Latin America Infliximab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
Brazil
Mexico
Rest of Latin America

Middle East & Africa Infliximab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
GCC Countries
South Africa
Rest of Middle East & Africa

Why should buy this report:
To receive a comprehensive analysis of the prospects for the global Infliximab Biosimilar market
To receive an industry overview and future trends of the Infliximab Biosimilar market
To analyze the Infliximab Biosimilar market drivers and challenges
To get information on the Infliximab Biosimilar market value (US$Mn) forecast to 2030
Significant investments, mergers & acquisitions in the Infliximab Biosimilar market industry

For More Information @ https://www.insightaceanalytic.com/customisation/1060

Corporate Office :
Office No.3050, 3rd Floor Marvel Fuego, Magarpatta Rd, Hadapsar, Pune, Maharashtra 411028

Sales Office (U.S.) :
344 Grove St Unit #967 Jersey City, NJ 07302
info@insightaceanalytic.com

info@insightaceanalytic.com
North America:
+1 551 226 6109
Asia:
+91 79 72967118

This release was published on openPR.